EGPS 2005.

Methods	RCT. Double‐masked. Placebo controlled. Multicenter (18).
Participants	1081 people with OHT. 99.9% caucasian. Inclusion criteria: IOP between 22 and 29 mmHg, 2 normal and reliable visual fields, normal optic discs (stereophoto), PEX allowed (below 2%), normal optic discs in both eyes (stereophoto), open angle, PEX and PDS allowed. Exclusion criteria: visual acuity below 20/40, previous intraocular surgery, previous laser trabeculoplasty within 3 months, secondary causes of elevated IOP.
Interventions	Dorzolamide 2% 3 times daily. Placebo.
Outcomes	Incidence of reproducible visual field defects. Incidence of reproducible optic disc changes (stereophoto).
Notes	Median follow up 55.3 months. 338 drop‐outs: 192 dorzolamide group (116 adverse events), 146 placebo group (51 adverse events). PEX and pigment dispersion in both groups 1 to 2 percent.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate